Read by QxMD icon Read

chronic obstructive pulmonary ivabradine

Michel Komajda
Ivabradine is a blocker of the funny current channels in the sinoatrial node cells. This results in pure heart rate reduction when elevated without direct effect on contractility or on the vessels. It was tested in a large outcome clinical trial in stable chronic heart failure (CHF) with low ejection fraction, in sinus rhythm, on a contemporary background therapy including betablockers (SHIFT: Systolic Heart Failure Treatment with the If inhibitor Trial).The primary composite endpoint (cardiovascular mortality or heart failure hospitalization) was reduced by 18% whereas the first occurrence of heart failure hospitalizations was reduced by 26%...
2017: Handbook of Experimental Pharmacology
Kareem Mahmoud, Hussien Heshmat Kassem, Essam Baligh, Usama ElGameel, Yosri Akl, Hossam Kandil
Increased sympathetic tone and use of bronchodilators increase heart rate and this may worsen functional capacity in patients with chronic obstructive pulmonary disease (COPD). The aim of this study was to look at the short-term effect of the heart rate lowering drug ivabradine on clinical status in COPD patients.We randomised 80 COPD patients with sinus heart rate ≥90 bpm into either taking ivabradine 7.5 mg twice per day or placebo for two weeks. We assessed all patients using the modified Borg scale and 6-minute walk test at baseline and then again 2 weeks after randomisation...
October 2016: Clinical Medicine: Journal of the Royal College of Physicians of London
Yihong Sun, Jinming Yu, Dayi Hu
OBJECTIVE: To observe the current status of β-blocker (BB) use and heart rate control in Chinese patients with stable coronary artery disease (SCAD) based on subgroup data of the prospective observational longitudinal registry of patients with stable coronary artery disease (CLARIFY). METHODS: The CLARIFY study is an international prospective observational registry of outpatients with SCAD. From November 2009 to July 2010, patients with SCAD were enrolled, and demographic information, clinical indicators, medication and blood flow reconstruction were collected...
January 2016: Zhonghua Xin Xue Guan Bing za Zhi
Michael Böhm, Michele Robertson, Ian Ford, Jeffrey S Borer, Michel Komajda, Ingrid Kindermann, Christoph Maack, Mitja Lainscak, Karl Swedberg, Luigi Tavazzi
Incidence of chronic heart failure (HF) increases with age and cardiovascular (CV) morbidity. Co-morbidities increase hospitalization and mortality in HF, and non-CV co-morbidities may lead to preventable hospitalizations. We studied the impact of co-morbidities on mortality and morbidity in Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial, and investigated whether the impact of ivabradine was affected by co-morbidities. We analyzed the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trialpopulation, with moderate-to-severe HF and left ventricular dysfunction (in sinus rhythm with heart rate at rest ≥70 beats/min), according to co-morbidity: chronic obstructive pulmonary disease, diabetes mellitus, anemia, stroke, impaired renal function, myocardial infarction, hypertension, and peripheral artery disease...
December 15, 2015: American Journal of Cardiology
Massimo Pozzoli, Luigi Tavazzi
BACKGROUND: Limited data are available regarding specific differences among countries in demographic and clinical characteristics and treatment of patients with stable coronary artery disease. METHODS: CLARIFY is an international, prospective and longitudinal registry including more than 33 000 patients with stable coronary artery disease enrolled in 45 countries worldwide. Data were used to compare the characteristics of patients enrolled in Italy with those enrolled in Europe and in the rest of the world...
April 2014: Giornale Italiano di Cardiologia
Ivano Bonadei, Enrico Vizzardi, Edoardo Sciatti, Valentina Carubelli, Carlo Mario Lombardi, Antonio D'Aloia, Marco Metra
Results of recent clinical trials in patients with stable angina and chronic heart failure have successfully demonstrated a beneficial role of use of ivabradine in addition to the conventional therapy. Based on the results of these trials, the aim of our review was to give an overview of the literature about the use of ivabradine in clinical settings outside its usual purpose.
August 2014: Cardiovascular Therapeutics
Rustem Zulkarneev, Naufal Zagidullin, Guzel Abdrahmanova, Uta C Hoppe, Shamil Zagidullin
Accelerated sinus rhythm is an important side effect of inhaled salbutamol which is especially harmful in patients with chronic obstructive pulmonary disease (COPD) and coronary heart disease (CHD). Cross-over, randomized, open label study design. 20 patients (18 males and two females) with COPD stage II-IV and comorbide CHD NYHA class I-III were included. Spirometry with 400 mg salbutamol inhalation was performed at two consecutive days of the study. Patients in group I were prescribed 5 mg ivabradine per os 3 h before salbutamol inhalation solely on the first day of the study and patients of group II received 5 mg ivabradine only on the second day of the study...
2012: Pharmaceuticals
L Tavazzi, K Swedberg, M Komajda, M Böhm, J S Borer, M Lainscak, M Robertson, I Ford
BACKGROUND: Heart failure (HF) and chronic obstructive pulmonary disease (COPD) frequently coexist, with undefined prognostic and therapeutic implications. We investigated clinical profile and outcomes of patients with chronic HF and COPD, notably the efficacy and safety of ivabradine, a heart rate-reducing agent. METHODS: 6505 ambulatory patients, in sinus rhythm, heart rate ≥ 70 bpm and stable systolic HF were randomised to placebo or ivabradine (2.5 to 7.5mg bid)...
December 10, 2013: International Journal of Cardiology
É Kh Akhmetzianova, V V Gaĭnitdinova, A B Bakirov, O A Bogoroditskaia, I R Timershina
In order to assess effect of If-channel blocker ivabradine on severity of pulmonary hypertension in chronic obstructive pulmonary disease (COPD) we studied 60 patients with III-IV stage COPD. We divided these patients into 2 groups with similar clinical characteristics and therapy. Patients of one of these groups received ivabradine (10 mg/day) for 2 weeks, patients of another served as controls. The use of ivabradine was associated with statistically significant lowering of pulmonary hypertension, heart rate, and increase of exercise tolerance without negative effects on myocardial contractility, electrophysiological parameters, or data of spirometry...
2012: Kardiologiia
George Andrikopoulos, Socrates Pastromas, Athanasios Kartalis, Konstantina Toli, Ioannis Mantas, Stylianos Tzeis, Christos Kyrpizidis, Christoforos Olympios, Athanasios J Manolis, Stefanos Foussas, Athanasios Kranidis, Athanasios Pras, Athanasios Pipilis, Dimitris Chryssos, Alexandros Gotsis, Athanasios Trikas, Dimitrios Richter, Dimitrios Alexopoulos, Fragiskos Parthenakis, George Theodorakis, Stavros Konstantinides, Panos Vardas
INTRODUCTION: Significant evidence shows that elevated heart rate (HR) is an independent risk factor in patients with coronary artery disease (CAD) and influences their prognosis. In addition, patients with chronic obstructive pulmonary disease (COPD) have more frequent episodes of angina and their compliance with heart rate agents, such as beta blockers, is poor. The purpose of the multicenter observational RYTHMOS study was to evaluate the role of heart rate management in the prognosis and quality of life in patients with CAD and COPD...
March 2012: Hellenic Journal of Cardiology: HJC
Sebastian Majewski, Sebastian Slomka, Ewa Zielinska-Wyderkiewicz, Maciej Ciebiada, Pawel Gorski
BACKGROUND: There is substantial evidence that heart rate (HR) is a powerful predictor of mortality in both normal individuals and in patients with cardiovascular disease. The use of β-adrenoceptor antagonists (β-blockers) has confirmed the importance of lowering elevated HR in a patient's prognosis. However, these agents can have undesirable adverse effects (AEs) and due to the risk of bronchoconstriction are contraindicated in patients with obstructive airway disease. A selective bradycardic agent, without such undesirable effects, could be of therapeutic interest...
June 1, 2012: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
A A Khamaeva, F I Belialov, L V Kerzina, O V Berezovskaia, E D Parshukova, G Iu Zakharova
We investigated impact of ivabradine on exercise capacity and quality of life in patients with stable angina and comorbid chronic obstructive pulmonary disease during treatment with -blockers. Ivabradine with -blockers reduced heart rate, increased exercise capacity and improved angina more effective than -blockers only. Quality of life associated with angina increased in patients with stage I and II chronic obstructive pulmonary disease. Addition of ivabradine to -blockers for 2 month did not produce adverse respiratory effects...
2012: Kardiologiia
Ermenegildo de Ruvo, Francesco Sebastiani, Luigi Sciarra, Alessandro Fagagnini, Leonardo Calo
We present the case of a patient with a heart failure episode induced by acute right ventricular pacing. After reversal of beta-blockers because of chronic obstructive pulmonary disease (COPD) exacerbation, the following sinus tachycardia caused a 2:1 atrioventricular block and consequent continuous right ventricular pacing. He was treated with the selective I(f) inhibitor ivabradine, that reduced both ventricular pacing percentage and heart rate without affecting atrioventricular conduction. Ivabradine may be a valuable option in treatment of patients with atrioventricular conduction disturbances...
September 2011: Indian Pacing and Electrophysiology Journal
F T Ageev, G V Makarova, I F Patrusheva, Ia A Orlova
The study was aimed to assess the efficacy and safety of treating coronary heart disease (CHD) patients complicated with COPD using the combination of tolerable doses of -blocker bisoprolol and inhibitor If-channel ivabradine, compared with bisoprolol alone. A total of 50 patients were included (88% men, mean age 62.8+/-7.2 years) with stable angina and clinical signs of bronchoobstruction (84% with COPD and 16% with bronchial asthma in remission phase). At the study start, all patients received bisoprolol, the dose of which was titrated until the clinical signs of intolerance (most common - bronchoobstruction) appeared or worsened...
2010: Kardiologiia
Małgorzata Kurpesa, Ewa Trzos, Karina Wierzbowska-Drabik, Tomasz Rechciński
A 56 year-old woman with a transplanted heart, with arterial hypertension and chronic pulmonary obstructive disease, was hospitalised because of palpitations, dyspnea, chest pain and oedema. After cyclosporine treatment she was diagnosed with renal failure, which was treated by hemodialysis. Heart rate (HR) at admission was 100, mean HR in 24-hour Holter monitoring was 106 bpm. Ivabradine was added to the treatment. The dose of 2.5 mg bid was doubled after three days. Mean HR in control Holter monitoring was 81...
June 2010: Kardiologia Polska
A D Komlev, A I Kuziaev, G M Laskin, V E Kuzenkova, M V Kolosova
AIM: To evaluate the effect of the I(f) channel blocker ivabradine on bronchial patency and the volume parameters of external respiration function in patients with chronic obstructive pulmonary disease (COPD) in remission in order to determine whether the drug may be used in patients with coronary heart disease (CHD) concurrent with COPD. SUBJECTS AND METHODS: Heart rate, bronchial patency, and lung volume were studied by body plethysmography in 59 patients with COPD before and 14 days after administration of ivabradine in a daily dose of 10 mg...
2010: Terapevticheskiĭ Arkhiv
N Iu Grigor'eva
Effect of therapy with 1-adrenoblocker bisoprolol and inhibitor of If channels ivabradine on parameters of 24-hour ECG monitoring (24hECGM) was studied in 64 patients with ischemic heart disease (stable angina) and chronic obstructive pulmonary disease (COPD). At the first stage all patients received bisoprolol. Parameters of external respiration function (ERF) and 24h ECG were registered before and after 4 months of bisoprolol administration. At stage 2 indications were determined for inclusion of ivabradine in the treatment scheme...
2009: Kardiologiia
Michal Tendera, Jeffrey S Borer, Jean-Claude Tardif
OBJECTIVES: The antianginal and anti-ischemic efficacy of ivabradine has been demonstrated in large-scale trials. Pooling trial data allowed for subpopulation analyses of ivabradine's antianginal efficacy. METHODS: Data on the frequency of angina attacks, short-acting nitrate consumption, and heart rate were pooled from 5 randomized trials in patients with stable angina pectoris receiving 5, 7.5, or 10 mg of ivabradine b.i.d. for 3 or 4 months. The subpopulations were defined according to age, sex, disease characteristics, and comorbidities (severity of angina, history of myocardial infarction, cerebrovascular disease, revascularization status, diabetes, asthma/chronic obstructive pulmonary disease, or peripheral vascular disease)...
2009: Cardiology
N M Kolomoets, V I Bakshiev, E G Zarubina, S V Usenko, N M Arkad'eva, T V Kostycheva, K U Uvaĭsova
Clinical efficiency of If-inhibitor ivabradin (Coraxan, Servier) in 40 patients with cardiorespiratory pathology (CRP) was studied. It was shown, that use of ivabradin in dose of 5 mg two times a day leaded to significant decrease in number of angina attacks in a week, and also in time of painless myocardial ischemia, decrease in heart rate at a day and during physical exercises, increase in 6 minutes walking distance and circadian index, oxygen saturation and partial tension, decrease in average pressure in pulmonary artery, increase in ejection fraction of left ventricle...
2008: Klinicheskaia Meditsina
N M Kolomoets, V I Baksheev, E G Zarubina
No abstract text is available yet for this article.
2008: Kardiologiia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"